Tax Credit For Rare Disease Or Conditions
The Orphan Drug Tax Credit applies to qualified clinical trial expenses designated for rare disease or conditions. These conditions are usually called “orphan drugs”.
A Nonrefundable Orphan Drug Tax Credit Of 50% Of Qualifying Expenses
The orphan drug tax credit covers 50% of the clinical testing expenses, reducing the costs of developing drugs and products for small patient population.
Tax News Updates:
Del Mar Pharmaceuticals Granted U.S. Orphan Drug Designation for ...
"This orphan drug designation along with encouraging research results represents ... and tax credits for clinical testing expenses conducted after orphan ...
Athersys Announces Positive Results of MultiStem(R) Clinical Trial ...
Athersys received orphan drug designation from the US Food and Drug Administration for ... study-design assistance, tax incentives and seven years of market ...
Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Our Q4 non-GAAP tax rate was 24.3%, benefiting from a higher level of orphan drug research credits in favorable settlements from prior-year audits.
Orphan Drug Changes Brewing at the FDA
FDA officials have pointed out that orphan drugs must prove probable benefit and ... application fee waivers, and tax credits for up to 50% of R&D costs.